LAIYANG, China, April 4, 2011 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (Nasdaq: JGBO) ("Jiangbo" or the "Company"), a pharmaceutical company with its principal operations in the People's Republic of China ("China"), today announced that the Company has appointed Bernstein & Pinchuk LLP as its new independent registered public accountants, effective March 30, 2011, replacing Frazer Frost, LLP, to begin providing services for the quarter ended March 31, 2011.
The decision to change accountants was approved by Jiangbo's audit committee and board of directors, following the notification by Frazer Frost that it did not intend to stand for re-appointment as the company's principal accountant for the next fiscal year.
Frazer Frost, LLP had no disagreements with the Company, on any matters of accounting principle or practice, financial statement disclosure, or auditing scope or procedure for the fiscal years ended June 30, 2010, 2009 and 2008, or for the subsequent interim period ended December 31, 2010.
"We look forward to developing a strong relationship with Bernstein & Pinchuk LLP to provide investors with timely and accurate financial reports," commented Mr. Linxian Jin, Chief Executive Officer of Jiangbo. "With a strong team of professionals in China and substantial senior level expertise in the U.S., we believe that Bernstein & Pinchuk LLP is well positioned to serve our needs as a U.S.-listed company."
About Jiangbo Pharmaceuticals, Inc.
Jiangbo is engaged in the research, development, production, marketing and sales of pharmaceutical products in China. The Company's operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong Province. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. For additional information, please visit the Company's website (www.jiangbopharma.com).
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers, product obsolescence, and risks to the Company's outlook for production at the Hongrui facility. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
Jiangbo Pharmaceuticals, Inc.
CCG Investor Relations
Mr. Jin Linxian,CEO
Mr. Crocker Coulson, President
Phone: +86 (535) 728-2397
Phone: (646) 213-1915
SOURCE Jiangbo Pharmaceuticals, Inc.